Lenadex


Combined with:

Revlimid

Indications and Reactions:

Role Indications Reactions
Secondary
Prophylaxis 34.8%
Multiple Myeloma 22.0%
Product Used For Unknown Indication 11.1%
Plasma Cell Myeloma 11.0%
Hypertension 4.0%
Drug Use For Unknown Indication 3.2%
Ill-defined Disorder 2.3%
Diabetes Mellitus 1.8%
Neuropathy Peripheral 1.8%
Adverse Event 1.7%
Angina Pectoris 1.4%
Constipation 1.0%
Hyperlipidaemia 0.6%
Unevaluable Event 0.6%
Refractory Cancer 0.6%
Insomnia 0.6%
Infection Prophylaxis 0.5%
Peripheral Nerve Disorder Nos 0.4%
Thrombosis Prophylaxis 0.4%
Hyperuricaemia 0.4%
Thrombocytopenia 16.8%
White Blood Cell Count Decreased 10.9%
Pneumonia 10.2%
Platelet Count Decreased 9.5%
Pyrexia 7.5%
Neutropenia 5.9%
Neutrophil Count Decreased 4.7%
Rash 4.3%
Sepsis 3.6%
White Blood Cell Count Increased 3.5%
Tetany 3.4%
Tonsillitis 3.4%
Upper Respiratory Tract Inflammation 2.8%
Thrombosis 2.1%
Urticaria 2.0%
Delirium 1.9%
Gamma-glutamyltransferase Increased 1.9%
Hepatic Function Abnormal 1.9%
Interstitial Lung Disease 1.9%
Renal Failure 1.9%
Concomitant
Plasma Cell Myeloma 42.9%
Prophylaxis 17.1%
Pneumonia Aspiration 8.6%
Febrile Neutropenia 5.7%
Hypertension 5.7%
Multiple Myeloma 5.7%
Depression 2.9%
Diabetes Mellitus 2.9%
Dyslipidaemia 2.9%
Palliative Care 2.9%
Thrombosis Prophylaxis 2.9%
Liver Disorder 25.0%
Liver Function Test Abnormal 25.0%
Plasma Cell Myeloma 25.0%
Sepsis 25.0%

Drug Data